Cargando…

Huaier Extract Inhibits Prostate Cancer Growth via Targeting AR/AR-V7 Pathway

The androgen receptor (AR) plays a pivotal role in prostatic carcinogenesis, and it also affects the transition from hormone sensitive prostate cancer (HSPC) to castration-resistant prostate cancer (CRPC). Particularly, the persistent activation of the androgen receptor and the appearance of androge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Zhengfang, Liu, Cheng, Yan, Keqiang, Liu, Jikai, Fang, Zhiqing, Fan, Yidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940541/ https://www.ncbi.nlm.nih.gov/pubmed/33708629 http://dx.doi.org/10.3389/fonc.2021.615568

Ejemplares similares

GABARAPL1 Promotes AR+ Prostate Cancer Growth by Increasing FL-AR/AR-V Transcription Activity and Nuclear Translocation
por: Su, Bing, et al.
Publicado: (2019)

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
por: Labaf, Maryam, et al.
Publicado: (2022)

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
por: Wüstmann, Neele, et al.
Publicado: (2023)

Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer
por: Sugiura, Masahiro, et al.
Publicado: (2020)

Baicalein suppresses the androgen receptor (AR)-mediated prostate cancer progression via inhibiting the AR N-C dimerization and AR-coactivators interaction
por: Xu, Defeng, et al.
Publicado: (2017)

Regulation of AR mRNA translation in response to acute AR pathway inhibition
por: Somasekharan, Syam Prakash, et al.
Publicado: (2021)

Emerging proteins involved in castration-resistant prostate cancer via the AR-dependent and AR-independent pathways (Review)
por: Feng, Kangle, et al.
Publicado: (2023)

LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance
por: Zhang, Boya, et al.
Publicado: (2021)

TMEM158 expression is negatively regulated by AR signaling and associated with favorite survival outcomes in prostate cancers
por: Huang, Jian, et al.
Publicado: (2022)

AR Pathway Is Involved in the Regulation of CX43 in Prostate Cancer
por: Chen, Ruibao, et al.
Publicado: (2015)

Development and feasibility evaluation of an AR-assisted radiotherapy positioning system
por: Zhang, Gongsen, et al.
Publicado: (2022)

Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer
por: Hamid, Agus Rizal A. H., et al.
Publicado: (2021)

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
por: Narayanan, Ramesh
Publicado: (2020)

Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications
por: Zhao, Pei, et al.
Publicado: (2019)

Integral Analysis of the RNA Binding Protein-associated Prognostic Model for Renal Cell Carcinoma
por: Qin, Xin, et al.
Publicado: (2021)

$^{43}$Ar and $^{44}$Ar
por: Hudis, J, et al.
Publicado: (1970)

$^{43}Ar$ and $^{44}Ar$
por: Hudis, J, et al.
Publicado: (1970)

To Be(Ar) Or Not to Be(Ar) – Jones Dilemma?
por: Andrews, Nicholas A., et al.
Publicado: (2022)

Triptolide Inhibits the AR Signaling Pathway to Suppress the Proliferation of Enzalutamide Resistant Prostate Cancer Cells
por: Han, Yangyang, et al.
Publicado: (2017)

Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells
por: Shafi, Ayesha A., et al.
Publicado: (2015)

Inhibiting CBP Decreases AR Expression and Inhibits Proliferation in Benign Prostate Epithelial Cells
por: Tang, Xingxing, et al.
Publicado: (2023)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

Prognostic and Predictive Value of Liquid Biopsy-Derived Androgen Receptor Variant 7 (AR-V7) in Prostate Cancer: A Systematic Review and Meta-Analysis
por: Khan, Tanzila, et al.
Publicado: (2022)

Kava Components Down-Regulate Expression of AR and AR Splice Variants and Reduce Growth in Patient-Derived Prostate Cancer Xenografts in Mice
por: Li, Xuesen, et al.
Publicado: (2012)

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients
por: Giesen, Alexander, et al.
Publicado: (2023)

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
por: Kallio, Heini M. L., et al.
Publicado: (2018)

Androgen Receptor-Mediated Growth Suppression of HPr-1AR and PC3-Lenti-AR Prostate Epithelial Cells
por: Kim, Young-Chae, et al.
Publicado: (2015)

Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
por: Makino, Tomoyuki, et al.
Publicado: (2021)

Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer
por: Khan, Farhan, et al.
Publicado: (2023)

Peptides disrupting TM4SF3 interaction with AR or AR-V7 block prostate cancer cell proliferation
por: Khatiwada, Prabesh, et al.
Publicado: (2023)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Selective degradation of AR-V7 to overcome castration resistance of prostate cancer
por: Liu, Yuan, et al.
Publicado: (2021)

AR, the cell cycle, and prostate cancer
por: Balk, Steven P., et al.
Publicado: (2008)

AR Signaling and the PI3K Pathway in Prostate Cancer
por: Crumbaker, Megan, et al.
Publicado: (2017)

On atmospheric $^{39}Ar$ and $^{42}Ar$ abundance
por: Cennini, P, et al.
Publicado: (1995)

Somatic Alterations Impact AR Transcriptional Activity and Efficacy of AR-Targeting Therapies in Prostate Cancer
por: Chauhan, Gaurav, et al.
Publicado: (2021)

Stilbene Induced Inhibition of Androgen Receptor Dimerization: Implications for AR and ARΔLBD-Signalling in Human Prostate Cancer Cells
por: Streicher, Wolfgang, et al.
Publicado: (2014)

Re-Expression of ERα and AR in Receptor Negative Endocrine Cancers via GSK3 Inhibition
por: Sharma, Vikas, et al.
Publicado: (2022)

Rapamycin inhibits AR signaling pathway in prostate cancer by interacting with the FK1 domain of FKBP51
por: Zhang, Jing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nt43mdtbkmq4eo4l2j5cdfjvhj